Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Researchers have found that Sotyktu, which inhibits the protein TYK2, protects insulin-producing beta cells and, at the same ...

This drug can interact with some other medications ... talk with your doctor or pharmacist. Certain TKIs lower the activity of an enzyme (protein) in your liver called UGT1A1.

Kinases are considered effective targets for drug development, especially with the notable success of kinase inhibitors in cancer treatment. Nonetheless, their capabilities in treating ...

Iclusig®, approved in China in September 2024, has demonstrated particular efficacy against T315I-mutated BCR::ABL1 disease that is resistant to first and second generation TKIs, with the OPTIC ...